ArticleFrontiers in pharmacology2026

Case Report: zanidatamab-based regimen as a potential later-line therapeutic option in HER2-amplified metastatic colorectal cancer.

Lin Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.